Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Midomafetamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 known ✓ | P31645 | 3/20 | 0.97 |
| ▸ | SLC6A2 known ✓ | P23975 | 2/20 | 0.97 |
| ▸ | SLC6A3 known ✓ | Q01959 | 2/20 | 0.97 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.97 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.97 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Midomafetamine SCHEMBL25233404 | 1.00 | TAAR1 (0.97) | TAAR1SLC6A4SLC6A2SLC6A3CYP2D6 | |
| Midomafetamine SCHEMBL25233250 | 1.00 | TAAR1 (0.97) | TAAR1SLC6A4SLC6A2SLC6A3CYP2D6 | |
| Midomafetamine SCHEMBL31158474 | 0.98 | TAAR1 (0.94) | TAAR1SLC6A4SLC6A2SLC6A3CYP2D6 | |
| Midomafetamine SCHEMBL896602 | 0.98 | TAAR1 (1.00) | TAAR1SLC6A4SLC6A2SLC6A3CYP2D6 | |
| Midomafetamine SCHEMBL15162286 | 0.98 | TAAR1 (1.00) | TAAR1SLC6A4SLC6A2SLC6A3CYP2D6 | |
| Midomafetamine SCHEMBL29353930 | 0.98 | TAAR1 (1.00) | TAAR1SLC6A4SLC6A2SLC6A3CYP2D6 | |
| Midomafetamine SCHEMBL44210 | 0.98 | TAAR1 (1.00) | TAAR1SLC6A4SLC6A2SLC6A3CYP2D6 | |
| Midomafetamine SCHEMBL24088997 | 0.98 | TAAR1 (1.00) | TAAR1SLC6A4SLC6A2SLC6A3CYP2D6 | |
| Midomafetamine SCHEMBL30064471 | 0.98 | TAAR1 (1.00) | TAAR1SLC6A4SLC6A2SLC6A3CYP2D6 | |
| Midomafetamine SCHEMBL2421248 | 0.95 | TAAR1 (0.94) | TAAR1SLC6A4SLC6A2SLC6A3CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 105 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12577222-B2 | Phenethylamine compounds salts, polymorphic forms and methods of use thereof | TERRAN BIOSCIENCES INC. (US) | 2026-03-17 | — | — | US | claimed |
| EP-4611738-A1 | COMPOSITIONS COMPRISING MDMA AND METHODS OF USING SAME | Lykos Therapeutics, Inc. (US) | 2025-09-10 | — | — | EP | claimed |
| US-20250134856-A1 | COMPOSITIONS COMPRISING MDMA AND METHODS OF USING SAME | MAPS PUBLIC BENEFIT CORPORATION | 2025-05-01 | — | — | US | claimed |
| US-20250134855-A1 | COMPOSITIONS COMPRISING MDMA AND METHODS OF USING SAME | MAPS PUBLIC BENEFIT CORPORATION | 2025-05-01 | — | — | US | claimed |
| US-20250127756-A1 | COMPOSITIONS COMPRISING MDMA AND METHODS OF USING SAME | MAPS PUBLIC BENEFIT CORPORATION | 2025-04-24 | — | — | US | claimed |
| US-20250127757-A1 | COMPOSITIONS COMPRISING MDMA AND METHODS OF USING SAME | MAPS PUBLIC BENEFIT CORPORATION | 2025-04-24 | — | — | US | claimed |
| EP-4433466-A2 | PHENETHYLAMINE COMPOUNDS SALTS, POLYMORPHIC FORMS AND METHODS OF USE THEREOF | Terran Biosciences Inc. (US) | 2024-09-25 | — | — | EP | claimed |
| US-20240285577-A1 | COMPOSITIONS COMPRISING MDMA AND METHODS OF USING SAME | MAPS PUBLIC BENEFIT CORPORATION | 2024-08-29 | — | — | US | claimed |
| WO-2024123706-A1 | COMPOSITIONS COMPRISING MDMA AND METHODS OF USING SAME | LYKOS THERAPEUTICS, INC. (US) | 2024-06-13 | — | — | WO | claimed |
| US-20240010628-A1 | METHODS OF MANUFACTURE OF R-MDMA | Mind Medicine, Inc. (US) | 2024-01-11 | — | — | US | claimed |
| WO-2023108277-A1 | CANNABINOID AND PSYCHEDELIC FORMULATIONS COMPRISING HYDROTROPIC AGENTS | AGILE PHARMACEUTICALS SOLUTIONS INC. (CA) | 2023-06-22 | — | — | WO | claimed |
| WO-2023092044-A2 | PHENETHYLAMINE COMPOUNDS SALTS, POLYMORPHIC FORMS AND METHODS OF USE THEREOF | TERRAN BIOSCIENCES, INC. (US) | 2023-05-25 | — | — | WO | claimed |
| US-20110236897-A1 | NOVEL MARKERS FOR DIAGNOSING BRAIN DISEASE CAUSED BY BRAIN INJURY AND USE THEREOF | Catholic University Industry Academic Cooperation Foundation (KR) | 2011-09-29 | — | — | US | claimed |
| US-20260132118-A1 | SALT FORMS OF R-MDMA AND METHODS USING THE SAME | EMPATHBIO INC (US) | 2026-05-14 | — | — | US | disclosed |
| US-12600708-B2 | Prodrug compounds of 3,4-methylenedioxymethamphetamine (MDMA) and methods of synthesizing the same | APOAPSIS HOLDINGS, LLC (US) | 2026-04-14 | — | — | US | disclosed |
| US-12577222-B2 | Phenethylamine compounds salts, polymorphic forms and methods of use thereof | TERRAN BIOSCIENCES INC. (US) | 2026-03-17 | — | — | US | disclosed |
| US-8877802-B2 | Antiparkinsonian action of phenylisopropylamines | Duke Univerity (US) | 2014-11-04 | — | — | US | disclosed |
| US-20110236897-A1 | NOVEL MARKERS FOR DIAGNOSING BRAIN DISEASE CAUSED BY BRAIN INJURY AND USE THEREOF | Catholic University Industry Academic Cooperation Foundation (KR) | 2011-09-29 | — | — | US | disclosed |
| WO-2007016190-A2 | ANTIPARKINSONIAN ACTION OF PHENYLISOPROPYLAMINES | DUKE UNIVERSITY (US) | 2007-02-08 | — | — | WO | disclosed |
| US-20070027208-A1 | Antiparkinsonian Action of Phenylisopropylamines | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2007-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250127756-A1 | COMPOSITIONS COMPRISING MDMA AND METHODS OF USING SAME | SLC6A3, SLC6A2, SLC18A1 | SLC6A4 6/4885SLC6A2 2/4885SLC6A3 1/4885 |
| US-12577222-B2 | Phenethylamine compounds salts, polymorphic forms and methods of use thereof | DRD2, DRD1, DRD3 | SLC6A4 59/4885SLC6A2 17/4885SLC6A3 5/4885 |
| US-12600708-B2 | Prodrug compounds of 3,4-methylenedioxymethamphetamine (MDMA) and methods of synthesizing the same | OPRM1, DRD3, SLC6A3 | SLC6A4 28/4885SLC6A2 16/4885SLC6A3 3/4885 |
| US-20070027208-A1 | Antiparkinsonian Action of Phenylisopropylamines | PNMT, SNCA, COMT | SLC6A4 178/4885SLC6A2 97/4885SLC6A3 36/4885 |
| US-20250127757-A1 | COMPOSITIONS COMPRISING MDMA AND METHODS OF USING SAME | SLC6A3, SLC6A2, SLC18A1 | SLC6A4 6/4885SLC6A2 2/4885SLC6A3 1/4885 |
| US-20250134856-A1 | COMPOSITIONS COMPRISING MDMA AND METHODS OF USING SAME | SLC6A3, SLC6A2, SLC18A1 | SLC6A4 6/4885SLC6A2 2/4885SLC6A3 1/4885 |
| US-20250134855-A1 | COMPOSITIONS COMPRISING MDMA AND METHODS OF USING SAME | SLC6A3, SLC6A2, SLC18A1 | SLC6A4 6/4885SLC6A2 2/4885SLC6A3 1/4885 |
| US-20240285577-A1 | COMPOSITIONS COMPRISING MDMA AND METHODS OF USING SAME | SLC6A3, SLC6A2, SLC18A1 | SLC6A4 6/4885SLC6A2 2/4885SLC6A3 1/4885 |
| US-20260132118-A1 | SALT FORMS OF R-MDMA AND METHODS USING THE SAME | SLC6A4, SLC6A3, SLC6A2 | SLC6A4 1/4885SLC6A2 3/4885SLC6A3 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.